Shares of Becton Dickinson (BDX) are up almost 12% so far this year, nearly doubling the return of the S&P Health Care SPDR ETF (XLV). Allen Bond, portfolio manager for the Jensen Quality Growth Fund (JENSX), says investors should stick with the syringe-maker in 2016. 'Its global market share is somewhere around 60% and we think that’s a tremendous competitive advantage for Becton Dickinson,' said Bond. 'And it’s a business that produces a lot of free cash flow that they can then invest for growth.' The Jensen Quality Growth Fund have risen 2% this year. Bond is also bullish on shares of Accenture (ACN) which have soared 20% year-to-date. Bond said the consultant’s stock has more room to run in the coming year because of its entrenched position with America’s multi-nationals. 'We think that gives them a large barrier to entry and a tremendous competitive advantage,' said Bond, adding that it consistently boasts a high return on capital. Shares of United Technologies (UTX) have fallen 18% thus far this year primarily due to problems in its emerging markets business. Nevertheless, Bond said he expects the industrial giant to make a comeback in the coming year because of its currently cheap valuation.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.